SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
777 W 41 St St, Suite 401, Miami Beach, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
Big Cypress Acquisition Corp. (to 10/22/2021)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 502 % +398%
Debt-to-equity 40.3 % -45.5%
Return On Equity -94.4 % +21.6%
Return On Assets -67.3 % +2.76%
Operating Margin -1.65K % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.23M shares -82.4%
Common Stock, Shares, Outstanding 9.23M shares -82.4%
Entity Public Float 30.7M USD -6.22%
Common Stock, Value, Issued 929 USD -82.4%
Weighted Average Number of Shares Outstanding, Basic 9.26M shares +76.7%
Weighted Average Number of Shares Outstanding, Diluted 9.26M shares +76.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 85.5K USD -98.7%
Revenue from Contract with Customer, Excluding Assessed Tax 2.78M USD -56.7%
Research and Development Expense 27.1M USD +39.7%
General and Administrative Expense 26.2M USD +123%
Operating Income (Loss) -51.8M USD -91.3%
Nonoperating Income (Expense) 6.21M USD +335%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -45.6M USD -67.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -45.6M USD -67.5%
Earnings Per Share, Basic -6.3 USD/shares +19.7%
Earnings Per Share, Diluted -6.3 USD/shares +19.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.17M USD +278%
Cash, Cash Equivalents, and Short-term Investments 15M USD -62%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 32.5M USD +940%
Property, Plant and Equipment, Net 16.1M USD -22%
Operating Lease, Right-of-Use Asset 1.06M USD +116%
Assets 53.8M USD +89.9%
Accounts Payable, Current 1.3M USD +19.7%
Employee-related Liabilities, Current 3.33M USD
Liabilities, Current 8.82M USD -4.29%
Operating Lease, Liability, Noncurrent 683K USD
Liabilities 16.9M USD +29.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 52.1K USD
Retained Earnings (Accumulated Deficit) -113M USD -67.8%
Stockholders' Equity Attributable to Parent 36.9M USD +142%
Liabilities and Equity 53.8M USD +89.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD -569%
Net Cash Provided by (Used in) Financing Activities -394K USD -9.63%
Net Cash Provided by (Used in) Investing Activities -31.4M USD -147126%
Common Stock, Shares Authorized 800M shares +63.3%
Common Stock, Shares, Issued 9.28M shares -82.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.5M USD -2041%
Interest Paid, Excluding Capitalized Interest, Operating Activities 66.2K USD -15.5%
Deferred Tax Assets, Valuation Allowance 19.2M USD +55.9%
Deferred Tax Assets, Gross 22.1M USD +39.5%
Operating Lease, Liability 1.07M USD +102%
Payments to Acquire Property, Plant, and Equipment 129K USD +506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.5M USD -101%
Lessee, Operating Lease, Liability, to be Paid 1.19M USD +120%
Property, Plant and Equipment, Gross 29.9M USD +1.06%
Operating Lease, Liability, Current 385K USD -27.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 393K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 452K USD +22.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +14.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 125K USD +777%
Lessee, Operating Lease, Liability, to be Paid, Year Three 86.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 10.3M USD +84.2%
Preferred Stock, Shares Issued 42.2K shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 90.2K USD
Operating Lease, Payments 918K USD +46.9%
Additional Paid in Capital 155M USD +76.3%
Preferred Stock, Shares Outstanding 42.2K shares
Depreciation, Depletion and Amortization 4.72M USD +27.8%
Deferred Tax Assets, Net of Valuation Allowance 2.86M USD -18.2%
Share-based Payment Arrangement, Expense 2.8M USD +11.5%
Interest Expense 317K USD -2.75%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%